Patheon and Senopsys Announce Alliance Nov 17, 2008
The alliance between Patheon and Senopsys is intended to deliver patient accepted pediatric formulations, line extension products and reformulated pharmaceutical products. These products will be optimized for palatability to increase patient compliance and improve health outcomes. (Canada Newswire)
Escalon(R) Reports First Quarter Fiscal 2009 Results Nov 14, 2008
" Non-GAAP Measures To supplement the Company's consolidated financial statements presented in accordance with GAAP, the Company has begun providing certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP net loss and non-GAAP loss per fully diluted share. The Company's reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards, but are not a substitute for, nor superior to, GAAP results. These... (PR Newswire)
KV Pharmaceutical delays Q2 filing Nov 14, 2008
Brentwood-based KV Pharmaceutical (NYSE: KVa, KVb) develops and markets pharmaceutical products, including branded and generic drugs. Reader Comments. (St. Louis Business Journal, MO)
TheraQuest's IND for Abuse Deterrent Strong Opioid (TQ-1015) Accepted by FDA Nov 13, 2008
About TheraQuest TheraQuest Biosciences, Inc. () is a private, development-stage pain management company building a diversified portfolio of pharmaceutical products to address a critical area of unmet medical need. Despite their limitations, current treatments for acute and chronic pain yield worldwide sales in excess of $30 billion. (PR Newswire)
High Temps Degrade Contact Lens Solution Nov 13, 2008
"Knowledge of the potential loss of antimicrobial activity of contact lens solutions and other pharmaceutical products when exposed to higher temperatures and the risk of such exposure when storing and transporting those products may help prevent such epidemics in the future," the researchers added. HealthDay. (MEDLINEplus)
Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy Nov 12, 2008
These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of... (PR Newswire)
KV Pharmaceutical to File Form 12b-25 on November 12, 2008 Nov 11, 2008
About KV Pharmaceutical Company KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products ... Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including... (PR Newswire)
BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update Nov 11, 2008
The Company's strategy includes revenue generation in the short-to-medium-term through the sale of natural health products and in the medium-to-long-term through development of a pipeline of pharmaceutical products. Revenue from collaboration agreement amounted to nil for the current quarter ($205,000 for the nine-month period), compared to $228,000 for the same period the previous year ($913,000 for the nine-month period). (PR Newswire)
Council awards design contract for new water plant Nov 11, 2008
The engineering firms will design the well field and plant, looking at alternatives to treating the increasing pollution found in the nation's water from pharmaceutical products. In answer to a question from Councilman Dave Ferris on the cost to build the plant, wells and distribution lines, Mach said the final number won't be known until the design has been completed. (Sioux City Journal, IO)
Lorus Therapeutics to Present At Rodman & Renshaw 10th Annual Healthcare Conference November 10-12, 2008 Nov 11, 2008
TORONTO, ONTARIO--(Marketwire - Nov. 11, 2008) - Lorus Therapeutics Inc. (TSX: - ; "Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that Dr. Aiping Young, President and CEO of Lorus, is invited to present a Company update at the Rodman and Renshaw 10th Annual Healthcare Conference being held at the New York Palace Hotel, New York. WHERE: New York Palace Hotel, Kennedy 1,... (CCNMatthews Press Releases)
Lorus Successfully Completes IND-Enabling Toxicology Studies for Lead Small Molecule Anticancer Drug LOR-253 Nov 10, 2008
TORONTO, ONTARIO--(Marketwire - Nov. 10, 2008) - Lorus Therapeutics Inc. (TSX: - ; "Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the successful completion of toxicology studies for its lead small molecule LOR-253 anticancer drug, formerly known as LT-253. LOR-253 represents a new targeted approach in cancer drug development, by inducing KLF4, a tumor... (CCNMatthews Press Releases)
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST Nov 8, 2008
About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. (PR Newswire)
ETHEX Corporation Initiated Nationwide Voluntary Recalls of Specific Lots of Five Generic Products Due to the Potential for Oversized Tablets Nov 8, 2008
Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product... (PR Newswire)
Health Care Spinoff Covidien Uses Diversity To Avoid Big Dip Nov 8, 2008
Covidien's imaging unit sells radioactive isotopes and related pharmaceutical products for disease diagnosis and treatment, as well as contrasting agents used in imaging. The firm's medical supply line includes wound-care products; operating room supplies, electrodes, needles and syringes, as well as incontinence products. (Investors Business Daily)
Takeda Wins Appeal Ruling Blocking Teva From Generic of Heartburn Medicine Nov 8, 2008
The drug was sold by TAP Pharmaceutical Products Inc., a former venture between Osaka-based Takeda and. The companies split the venture, with Takeda getting Prevacid. (Bloomberg -- Japan)
SemBioSys announces third quarter 2008 financial and operational results Nov 7, 2008
In addition to its pharmaceutical products, SemBioSys' subsidiary, Botaneco Specialty Ingredients Inc., is selling oleosome-based all natural products in the global personal care ingredient market. More information is available and can be accessed at or This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar... (Canada Newswire)
Informex to Introduce the GreenExchange at InformexUSA Nov 6, 2008
D., Rctor, DSM Pharmaceutical Products, will speak on the topic of sustainability through metabolic pathway engineered bugs ... D., Rctor, DSM Pharmaceutical Products Christopher E. Gann, Chief Executive Officer, Genomatica, Inc. In Search of Green Chemistry Excellence Since 1995, dozens of green chemical products have become commercially viable in the marketplace while a countless number of chemical production processes have been modified for greener reaction conditions. (PR Newswire)
* MEDIPHAR TAIPEI: MEDIPHAR TAIPEI professional medical exhibition and vital procurement platform Nov 6, 2008
These include: Italys largest producer/distributor of medical equipment and pharmaceutical products Artsana SPA Group (annual sales US$1. 8bn), South Korean medical instrument exporter/importer Samsung Coration (grossing US$9. (Taipei Times, Taiwan -- World)
Paladin Reports Record Third Quarter 2008 Financial Results Nov 6, 2008
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. (CCNMatthews Press Releases)
China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results Nov 5, 2008
Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit. (PR Newswire)
'Opt Out' System Could Solve Donor Organ Shortage, Says Researcher Nov 3, 2008
Dr Troyer says there is currently an illegal global trade in most body parts, with teeth, nails and bones being sold on the black market to be used as pharmaceutical products and skin being used to treat burns victims. Organs such as kidneys are also being sold by living donors for large sums of money, with organs from the third world sometimes being used for first world patients who are desperate for a life-saving operation. (Science Daily)
Former Telomolecular CEO Clarifies SEC Settlement Nov 3, 2008
According to Mr. Sarad, "I had no practical way to litigate the government and just wanted to put this unfortunate episode of my career behind me. Resigning from Telomolecular was truly heartbreaking for me given the many years of very hard work. We were all working in the interests of our investors and in the interests of science. The number of extraordinary assets and opportunities the company possesses is impressive and I believe the new CEO will break into global pharmaceutical markets with... (Yahoo News -- Press Releases)
3SBio Inc. Announces Preliminary Third Quarter 2008 Results Nov 1, 2008
7 million) -- Affirms 2008 Full Year Guidance SHENYANG, China, Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: ) ("3SBio" or "the Company"), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announced today that it expects to recognize a one-time impairment charge of approximately RMB19 ... About 3SBio Inc. 3SBio Inc. is a leading, fully integrated biotechnology company focused on... (PR Newswire)
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Nov 1, 2008
These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products, including the results of any clinical programs with respect to TREANDA or the timing or approval of any current or future filings for regulatory approval of TREANDA or other Cephalon compounds; interpretation of clinical results, particularly with respect to the TREANDA clinical trials; manufacturing development and capabilities; market prospects for... (PR Newswire)
Biosynthetics production with detours Nov 1, 2008
These include Pseudomonas putida: It produces chemicals, pharmaceutical products, degrades waste and toxins. It also plays an important role in manufacturing high-quality substances for industry. (EurekAlert!)
Economic Update: You Should Invest (in Your Appearance) Oct 30, 2008
According to Jeffrey Adelglass, M.D., F.A.C.S., Medical Director and Chief of Surgery of SKINTASTIC Medical and Surgical Rejuvenation Center of Plano, Texas, "We live in an amazing time. Until several short years ago, all the beauty world really had to offer was makeup to cover-up the truth, cold-cream, soaps and astringents to remove the makeup prior to re-application, and an abundance of 'snake-oil' cellulite 'cures.' Decade after decade, women faithfully lined up at the corner drug store to... (PR Newswire)
Hai-O sees 5% growth in sales Oct 30, 2008
Hai-O is engaged in the manufacture, wholesaling and MLM of traditional herbal and pharmaceutical products that mainly come from China. On the weaker economic environment, Tan said it was an opportunity for the company as people would be more open to taking a second, or part-time, job. (The Star Online, Malaysia -- Business)
Grupo Casa Saba Quarterly Earnings Report 3Q08 Oct 29, 2008
96 million Grupo Casa Saba ("Saba", "GCS", "the Company" or "the Group"), one of the leading Mexican distributors of pharmaceutical products, beauty aids, personal care and consumer goods, general merchandise, publications and other products announces its consolidated financial and operating results for the third quarter of 2008. QUARTERLY EARNINGS NET SALES During the third quarter, GCS's sales were $6,682. (PR Newswire)
Credit Crunch Threatens New Medicines Oct 29, 2008
28, 2008) The global financial crisis could seriously delay the discovery and production of many new life-saving medicines, warns a major international conference on October 27. Investment into research for new drugs - which globally runs into the billions is now seriously at threat as former investors in the drug companies shy away as a result of the economic meltdown. (Science Daily)
Teva and Barr Provide Update on Acquisition Oct 28, 2008
Important factors that could cause or contribute to such differences include whether and when the proposed acquisition will be consummated and the terms of any conditions imposed in connection with such closing, Teva's ability to rapidly integrate Barr's operations and achieve expected synergies, diversion of management time on merger-related issues, Teva and Barr's ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final... (PR Newswire)
QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System Oct 28, 2008
We plan to continue to investigate additional doses to see if efficacy may be further enhanced. " "The Latanoprost Punctal Plug Delivery System represents one of the most exciting exploratory programs addressing the unmet medical need of poor compliance and adherence patterns to treatment regimens seen in glaucoma and ocular hypertensive patients," said Lou Cantor, MD, Director, Glaucoma Service, Indiana University School of Medicine, Department of Ophthalmology and a QLT Clinical Advisory Board... (Canada Newswire)
QLT announces third quarter results for 2008 Oct 28, 2008
Our research and development efforts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. (Canada Newswire)
Improving the Use of Drugs Through Genes Oct 24, 2008
That's because some genetic variations that turn up in gene testing affect how people respond to pharmaceutical products. My liver enzymes might be speed demons when it comes to clearing drugs from my blood, while yours work far more slowly. (Yahoo News -- Pharmaceutical Industry News)
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells Oct 24, 2008
Thallion Pharmaceuticals Inc. (TSX: - ) is a biotechnology company developing pharmaceutical products in the areas of oncology and infectious disease. Thallion has three clinical programs at a Phase II, or later, stage of development. (CCNMatthews Press Releases)
Safety Problems For Biological Products Documented Oct 23, 2008
"Given the current imperfect process for approval and the flawed postmarketing surveillance system, the drug and device regulation process is at best an inexact and incomplete science. Until these deficiencies in the system are remedied, some patients inevitably will continue to experience harm from the use of newly marketed products as well as from use of other approved medications. Just as with other consumer products that cause harms, consumers (i.e., patients) who are injured by defective... (Science Daily)
Aso bats for EPA with India Oct 21, 2008
Although Japan has zero duty on around 30 per cent of its chemical and pharmaceutical products, its stringent approval and product registration act as a barrier to Indian exports. Sections: | | | | | | | | | | The Hindu Group: | | | | Group Sites. (Hindu)
Novartis Posts 32 Percent Rise in 3Q Net Profit Oct 21, 2008
"We have achieved strong results in the third quarter of 2008 despite significant volatility in the global economic environment," the company said, adding that it was "rejuvenating" its portfolio with recently launched pharmaceutical products providing US$2. 1 billion in sales so far this year. (ABC News -- Wire)
Covidien launches $100 million plant expansion, adds jobs Oct 21, 2008
The expansion means 30 new jobs in scientific and research and development areas, said JoAnna Schooler, director of communications for Covidien s Imaging Solutions and Pharmaceutical Products operations in Hazelwood ... The Covidien Imaging Solutions and Pharmaceutical Products division is based in the St. Louis area. (St. Louis Business Journal, MO)
Church promotes Small Medium Scale Enterprises Oct 20, 2008
Members exhibited pharmaceutical products, dresses, banku, fufu, locally made shoes, table cloths, beads and ornaments and others advertised their services. The Reverend Patrick Kofi Ntim Manteaw, Pastor in charge of the church, said there was the need for members to know each other in terms of what businesses they are involved in. (Ghana Web, Ghana)
McKinney: McKinney man implicated in global spam ring Oct 20, 2008
The complaint claims Smith is liable for allegedly making false claims about pharmaceutical products and Atkinson is liable for alleged false statements about all of the messages claims, according to the FTC.. FTC officials also claim the companies processed more than 400,000 in Visa charges for these products, according to the New York Times. (McKinney Courier-Gazette, TX)
Barr Revises Timing of Its Earnings Conference Call to Discuss the Results for the Third Quarter of Calendar 2008 to 9:00 AM Eastern Time Oct 18, 2008
Those factors include, without limitation: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; market and customer acceptance and demand for our pharmaceutical products; our dependence on... (PR Newswire)
Canada, EU working towards 'historic' agreement: PM Oct 18, 2008
and I hope The EU is capable forcing canada to stop using so much pharmaceutical products in our food supply. Jason Daniel Baker, TorontoThis is a pleasant surprise and I am astonished by how quickly this is happening. (CTV.ca)
Investor That Lost Over $600,000 in Several Morgan Keegan Mutual Funds Files An Arbitration Claim Against Morgan Keegan, Senior Partners Paul J. Napoli and Marc Jay Bern of the Law Firm Napoli Bern Ripka Announce -- RHY, RMH, RMA, and RSF Oct 18, 2008
In addition to Stock Fraud claims, the firm represents clients in personal injury matters, medical and other professional malpractice, and pharmaceutical products liability (diet drugs, Rezulin and Trasylol) as well as toxic tort and other environmental claims. The firm has more than 60 years of combined litigation experience in trial and appellate courts. (Primezone Releases)
Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application Oct 17, 2008
Daiichi Sankyo, Inc. ) headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. About Eli Lilly and Company Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind. (PR Newswire)
E-Mail Enhancement Oct 16, 2008
The FTC named Atkinson as responsible for product claims while Smith was named as liable for claims made on pharmaceutical products. The Federal Trade Commission filed its complaint with an Illinois district court on Oct. 6 and said its Midwest region in Chicago is handling the case. (Forbes -- Technology)
Pharma Mergers Boom Despite Global Credit Woes Oct 15, 2008
"The industry itself is facing severe pricing pressures in America and Europe and Japan, and there is the need to get new innovative pharmaceutical products into the market," says Thomas Reid, head of 's corporate department. The firm has represented , , Roche, and Shionogi in recent merger and licensing transactions. (Law.com)
Lorus Therapeutics Announces Receipt of Milestone Payment and Extension of Exclusive License Agreement for Virulizin(R) Oct 15, 2008
TORONTO, ONTARIO--(Marketwire - Oct. 15, 2008) - Lorus Therapeutics Inc. (TSX: - ; NYSE-A:LRP)("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that it has received a milestone payment of US$150,000 from Zor Pharmaceuticals LLC ("ZOR"), a subsidiary of Zoticon Bioventures Inc., as it has achieved the milestone of raising the first tranche in financing for the development of... (CCNMatthews Press Releases)
Acura Pharmaceuticals and King Pharmaceuticals Announce Positive Top Line Results of Key Clinical Study Assessing Abuse Liability Oct 13, 2008
King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and life-cycle management ... Some important factors which may cause actual results to differ materially from the forward-looking statements... (Primezone Releases)
Lorus Therapeutics Announces Voluntary Delisting From the NYSE Alternext Oct 11, 2008
TORONTO, ONTARIO--(Marketwire - Oct. 10, 2008) - Lorus Therapeutics Inc. (TSX: - ; NYSE-A:LRP) ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that it has submitted written notice to the NYSE Alternext U.S., LLC ("NYX") (formerly American Stock Exchange) of its intention to voluntarily delist its common shares from NYX. The Company expects that the delisting will become... (CCNMatthews Press Releases)
F&S biodfuel plant ready for sale Oct 11, 2008
It can use a variety of raw materials such as yellow grease, sugar cane, rapeseed or canola oil to produce biodiesel fuel, as well as glycerine, a byproduct that can be sold for use in pharmaceutical products and other uses. Helming said he is also close to selling Fs stake in Grease Guys, a company that produces "feedstock," or the raw material used to make biofuel, but declined to say how much that might be worth. (Republican-American)
FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes Oct 10, 2008
As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website. (PR Newswire)
2 Major Japanese Wholesalers Considering Merger Oct 10, 2008
and Alfresa Holdings Corp. , a wholesaler specializing in pharmaceutical products and medical equipment, are considering merging into a single entity, informed sources said Thursday. "> 2 Major Japanese Wholesalers Considering Merger Tokyo, Oct 9, 2008 (Jiji Press) - Major Japanese wholesaler Mediceo Paltac Holdings Co. and Alfresa Holdings Corp. , a wholesaler specializing in pharmaceutical products and medical equipment, are considering merging into a single entity, informed sources said... (JCN Network, Japan)
Shoppers Drug Mart Corporation to release third quarter results on November 6 and hold analyst conference call Oct 8, 2008
In addition to its retail store network, the Company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, and MediSystem Technologies Inc., a provider of pharmaceutical products and services to long-term care facilities in Ontario and Alberta. SEDAR: 00016987EF. (Canada Newswire)
Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration Oct 6, 2008
Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural... (PR Newswire)
Bayer deal means expansion of western Ky. plant Oct 5, 2008
The deal lays the foundation for the production of several pharmaceutical products to be grown inside tobacco plants at the Owensboro company. Construction on the expansion in Owensboro will begin later this month. (FOX19.com, OH)
Hai-O's earnings fast-expanding, dividend yield likely to be 12% Oct 3, 2008
The company, which is involved in multi-level marketing (MLM) of health and pharmaceutical products, had maintained a net cash position of RM81. 5mil as at end-April 2008. (The Star Online, Malaysia)
Takeda Established a New Company for Asian Sales & Marketing Oct 3, 2008
Takeda Established a New Company for Asian Sales ting. Takeda Established a New Company for Asian Sales ting. (JCN Network, Japan)
ForteBio gets $25M in 3rd round Sep 25, 2008
a supplier of label-free technology for life science and pharmaceutical products, said late Tuesday it closed a third round of funding with $25 million. Menlo Park-based ForteBio said the round was led by New York-based. (San Jose Business Journal, CA)
Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference Sep 24, 2008
These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. SOURCE Ironwood Pharmaceuticals; Forest Laboratories, Inc.. (PR Newswire)
Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes Sep 24, 2008
As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate Web site. (PR Newswire)
ForteBio, Inc. Closes $25 Million In Series C Financing Sep 24, 2008
Sept. 23 /PRNewswire/ -- ForteBio(R), Inc., a leading supplier of label-free technology that accelerates the development of life science and pharmaceutical products, today announced the closing of $25 million in Series C financing, led by OrbiMed Advisors, a top global healthcare investment firm. MPM Capital also participated as a new investor in this financing round, as did existing investors Alloy Ventures, Latterell Venture Partners, The Vertical Group and Versant Ventures. (PR Newswire)
Job Information: Sr. Professional Representative Urology - Jacks Sep 24, 2008
Extensive knowledge of sales processes and pharmaceutical products and industry. Excellent communication, facilitation and presentation skills. (The Clarion-Ledger)
Kobayashi Pharmaceutical Reports Financial Results for the First Quarter Ended June 30, 2008 Sep 22, 2008
In addition, although sales of OTC pharmaceutical products for summer were flat as a result of unseasonable weather, the overseas body warmer business and business related to existing products, such as OTC pharmaceutical product Nicitol 85, which promotes the breakdown and consumption of abdominal fat, mouth freshener Breath Care, and the toilet cleaner Bluelet, were firm, which led to sales growing 1. 4% (351 million yen) year on year to 25,574 million yen. (JCN Network, Japan)
New Pegloticase and Treatment Failure Gout Data to be Featured in Six Abstracts At American College of Rheumatology 72nd Annual Scientific Meeting Sep 22, 2008
Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, Puricase(r) (pegloticase) for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. (Primezone Releases)
Melissa Essential Oil Sep 21, 2008
Today, France is still a big user of Melissa leaves in herbal and other pharmaceutical products. The Adulteration of Melissa Essential Oil. (Suite101.com)
